Claritas Pharmaceuticals Inc
Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was formerly known as Kalytera Therapeutics, Inc. and changed its name to Claritas Pharmaceuticals, Inc. in April 2021. Claritas Pharmaceuticals, Inc. was founded in 2014 and is based in San Rafael, California.
Claritas Pharmaceuticals Inc (CLAZF) - Total Liabilities
Latest total liabilities as of September 2021: $7.74 Million USD
Based on the latest financial reports, Claritas Pharmaceuticals Inc (CLAZF) has total liabilities worth $7.74 Million USD as of September 2021.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Claritas Pharmaceuticals Inc - Total Liabilities Trend (2005–2020)
This chart illustrates how Claritas Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Claritas Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Claritas Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wolf Energy Services Inc.
PINK:WOEN
|
USA | $3.96 Million |
|
Everyman Media Group plc
LSE:EMAN
|
UK | GBX162.73 Million |
|
Synergy Grid and Development Phils Inc
PSE:SGP
|
Philippines | ₱351.62 Billion |
|
DATANG INTL POW -H-
MU:BJI
|
Germany | €218.12 Billion |
|
Ingdan Inc
STU:7C3
|
Germany | €5.68 Billion |
|
PACIFIC CENTURY (PFQ.SG)
STU:PFQ
|
Germany | €191.14 Million |
|
Well Chip Group Berhad
KLSE:5325
|
Malaysia | RM247.22 Million |
Liability Composition Analysis (2005–2020)
This chart breaks down Claritas Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.70 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Claritas Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Claritas Pharmaceuticals Inc (2005–2020)
The table below shows the annual total liabilities of Claritas Pharmaceuticals Inc from 2005 to 2020.
| Year | Total Liabilities | Change |
|---|---|---|
| 2020-12-31 | $8.94 Million | -68.85% |
| 2019-12-31 | $28.69 Million | -42.44% |
| 2018-12-31 | $49.85 Million | -35.19% |
| 2017-12-31 | $76.91 Million | +3954.24% |
| 2016-12-31 | $1.90 Million | +848.50% |
| 2015-12-31 | $200.00K | -84.49% |
| 2014-12-31 | $1.29 Million | -72.16% |
| 2013-12-31 | $4.63 Million | -47.21% |
| 2012-12-31 | $8.78 Million | +21.18% |
| 2011-12-31 | $7.24 Million | -26.19% |
| 2010-12-31 | $9.81 Million | +86.90% |
| 2009-12-31 | $5.25 Million | +10.29% |
| 2008-12-31 | $4.76 Million | +19.50% |
| 2007-12-31 | $3.98 Million | +24623.36% |
| 2006-12-31 | $16.12K | -37.42% |
| 2005-12-31 | $25.75K | -- |